Clinical Trials | April 22, 2026
Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Subscribe To Our Newsletter & Stay Updated
